A Dyslipidemia Drug That is Dosed Once a Week Would Earn Nearly Double the Patient Share in the U.S. Than in Europe

Abbott/AstraZeneca's Certriad Will Become Decision Resources' Proprietary Clinical Gold Standard in 2013 and Through 2018

WALTHAM, Mass., April 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a dyslipidemia drug that is dosed once a week would earn 40 percent patient share in the U.S., according to surveyed U.S. primary care physicians (PCPs). In contrast, in Europe, such a drug would earn 23 percent patient share, according to surveyed European physicians. These estimated patient shares are comparable to shares achieved by sales-leading Pfizer's Lipitor (also known in Europe as Tahor, Sortis and Cardyl) in the United States and Europe in 2008. The magnitude of PCPs' patient share estimates indicates that a drug dosed once a week with similar cardio protective effects as Lipitor is highly appealing.

The new report entitled Dyslipidemia: Blockbuster Potential for Agents That Offer Improvements in Convenience finds that a therapy's effect on low-density lipoprotein cholesterol is the attribute that most influences U.S. surveyed PCPs prescribing decisions in the treatment of dyslipidemia. European PCPs indicate that effect on morbidity is the attribute that has the greatest influence on their prescribing decisions. Clinical data and the opinions of interviewed thought leaders indicate that Genzyme/Isis Pharmaceuticals' mipomersen and Abbott/AstraZeneca's fixed-dose combination Certriad have advantages over sales-leading Lipitor on this attribute.  

The report also finds that Certriad earns Decision Resources' proprietary clinical gold-standard status in 2013 and through 2018 because it combines the most potent statin, rosuvastatin, with fenofibric acid. Fenofibric acid reduces triglyceride levels and increases high-density lipoprotein cholesterol levels, so the combination targets three key lipid parameters and addresses mixed dyslipidemia more effectively than any other current or emerging therapy.

"The fenofibric acid/rosuvastatin fixed-dose combination will remain Decision Resources' clinical gold standard through 2018 because there are no other agents expected to launch during this time that will have a clinical profile superior to that of Abbott/AstraZeneca's Certriad," stated Decision Resources' Analyst Caroline Gates.

About the Report

Dyslipidemia: Blockbuster Potential for Agents That Offer Improvements in Convenience is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources, Inc.

Christopher Comfort


[email protected]

SOURCE Decision Resources